Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Imugene Limited ( (AU:IMU) ).
Imugene Limited announced the cessation of certain securities, including 14,796,793 restricted stock units and 6,666,666 options, due to unmet conditions. This development may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s operational strategies and future growth prospects.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
More about Imugene Limited
Imugene Limited is a biotechnology company focused on the development of innovative cancer immunotherapies. The company specializes in products that harness the immune system to treat and eradicate tumors, aiming to improve the lives of cancer patients globally.
Average Trading Volume: 24,219,722
Technical Sentiment Signal: Sell
Current Market Cap: A$119.5M
For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.